Health-related quality of life in women with breast cancer: a review of measures

被引：27

作者：

Salas, Maribel ^{[1
]}

Mordin, Margaret ^{[2
,3
]}

Castro, Colleen ^{[4
]}

Islam, Zahidul ^{[1
]}

Tu, Nora ^{[1
]}

Hackshaw, Michelle D. ^{[1
]}

机构：

[1] Daiichi Sankyo Inc, Epidemiol Clin Safety & Pharmacovigilance, 211 Mt Airy Rd,1A-453, Basking Ridge, NJ 07920 USA

[2] Univ Penn, CCEB CPeRT, Perelman Sch Med, Philadelphia, PA 19104 USA

[3] RTI Hlth Solut, Ann Arbor, MI USA

[4] RTI Hlth Solut, Res Triangle Pk, NC USA

来源：

BMC CANCER | 2022年 / 22卷 / 01期

关键词：

PROMs; Breast cancer; 5-DIMENSION EQ-5D-5L QUESTIONNAIRE; FUNCTIONAL ASSESSMENT; FACT-B; EUROPEAN ORGANIZATION; SYMPTOM INDEX; EORTC QLQ-C30; VALIDATION; THERAPY; RELIABILITY; VALIDITY;

D O I：

10.1186/s12885-021-09157-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background To identify and describe the breast cancer-specific health-related quality of life (HRQoL) instruments with evidence of validation in the breast cancer population for potential use in patients treated for breast cancer (excluding surgery). Methods We conducted a systematic literature review using PubMed, Embase, and PsycINFO databases to identify articles that contain psychometric properties of HRQoL instruments used in patients with breast cancer. Relevant literature from January 1, 2009, to August 19, 2019, was searched. Articles published in English that reported psychometric properties (reliability, validity) of HRQoL instruments were identified. Results The database search yielded 613 unique records; 131 full-text articles were reviewed; 80 articles presented psychometric data for instruments used in breast cancer (including generic measures). This article reviews the 33 full articles describing psychometric properties of breast cancer-specific HRQoL instruments: EORTC QLQ-C30, EORTC QLQ-BR23, FACT-B, FBSI, NFBSI-16, YW-BCI36, BCSS, QuEST-Br, QLICP-BR, INA-BCHRQoL, and two newly developed unnamed measures, one by Deshpande and colleagues (for use in India) and one by Vanlemmens and colleagues (for use among young women and their partners). The articles that described the EORTC QLQ-C30, QLQ-BR23, and FACT-B centered on validating translations, providing additional support for content validity, and demonstrating acceptability of electronic patient-reported outcome administration. Psychometric properties of the measures were acceptable. Several new measures have been developed in Asia with an emphasis on development on cultural relevance/sensitivity. Others focused on specific populations (i.e., young women with breast cancer). Conclusions Historically, there have been limited options for validated measures to assess HRQoL of patients with breast cancer. A number of new measures have been developed and validated, offering promising options for assessing HRQoL in this patient population. This review supports the reliability and validity of the EORTC QLQ-C30 and FACT-B; new translations and electronic versions of these measures further support their use for this population.

引用

页数：20

共 41 条

[1] Validity and reliability of the European Organization for Research and Treatment in Cancer Quality of Life Questionnaire (EORTC QLQ): experience from Kuwait using a sample of women with breast cancer [J].

Alawadhi, Shafika A. ;

Ohaeri, Jude U. .

ANNALS OF SAUDI MEDICINE, 2010, 30 (05) :390-396

[2] Reliability Estimates for the Arabic Versions of the Cancer Behavior Inventory-Brief and the Functional Assessment of Cancer Therapy-Breast [J].

Algamdi, Maaidah M. ;

Hanneman, Sandra K. .

JOURNAL OF NURSING MEASUREMENT, 2016, 24 (03) :388-398

[3]

Bener Abdulbari, 2017, J Family Med Prim Care, V6, P824, DOI 10.4103/jfmpc.jfmpc_17_17

[4] Third consensus on medical treatment of metastatic breast cancer [J].

Beslija, S. ;

Bonneterre, J. ;

Burstein, H. J. ;

Cocquyt, V. ;

Gnant, M. ;

Heinemann, V. ;

Jassem, J. ;

Koestler, W. J. ;

Krainer, M. ;

Menard, S. ;

Petit, T. ;

Petruzelka, L. ;

Possinger, K. ;

Schmid, P. ;

Stadtmauer, E. ;

Stockler, M. ;

Van Belle, S. ;

Vogel, C. ;

Wilcken, N. ;

Wiltschke, C. ;

Zielinski, C. C. ;

Zwierzina, H. .

ANNALS OF ONCOLOGY, 2009, 20 (11) :1771-1785

[5] An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 [J].

Bjelic-Radisic, V ;

Cardoso, F. ;

Cameron, D. ;

Brain, E. ;

Kuljanic, K. ;

da Costa, R. A. ;

Conroy, T. ;

Inwald, E. C. ;

Serpentini, S. ;

Pinto, M. ;

Weis, J. ;

Morag, O. ;

Astrup, G. Lindviksmoen ;

Tomaszweksi, K. A. ;

Pogoda, K. ;

Sinai, P. ;

Sprangers, M. ;

Aaronson, N. ;

Velikova, G. ;

Greimel, E. ;

Arraras, J. ;

Bottomley, A. .

ANNALS OF ONCOLOGY, 2020, 31 (02) :283-288

[6]

Bjelic-Radisic V., 2018, Ann Oncol, V29, pviii59, DOI [10.1093/annonc/mdy270.267, DOI 10.1093/ANNONC/MDY270.267]

[7]

Blazeby J, 2002, GUIDELINES DEVELOPIN

[8]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[9] ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].

Cardoso, F. ;

Costa, A. ;

Norton, L. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Blackwell, K. L. ;

Cardoso, M. J. ;

Cufer, T. ;

El Saghir, N. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Giordano, S. H. ;

Gligorov, J. ;

Goldhirsch, A. ;

Harbeck, N. ;

Houssami, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Kyriakides, S. ;

Lin, U. N. ;

Mayer, M. ;

Merjaver, S. D. ;

Nordstrom, E. B. ;

Pagani, O. ;

Partridge, A. ;

Penault-Llorca, F. ;

Piccart, M. J. ;

Rugo, H. ;

Sledge, G. ;

Thomssen, C. ;

van't Veer, L. ;

Vorobiof, D. ;

Vrieling, C. ;

West, N. ;

Xu, B. ;

Winer, E. .

BREAST, 2014, 23 (05) :489-502

[10] Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer [J].

Cerezo, O. ;

Onate-Ocana, L. F. ;

Arrieta-Joffe, P. ;

Gonzalez-Lara, F. ;

Garcia-Pasquel, M. J. ;

Bargallo-Rocha, E. ;

Vilar-Compte, D. .

EUROPEAN JOURNAL OF CANCER CARE, 2012, 21 (05) :684-691

← 1 2 3 4 5 →